UroGen Pharma Ltd. Reports New Financial Obligation
Ticker: URGN · Form: 8-K · Filed: 2024-09-24T00:00:00.000Z
Sentiment: neutral
Topics: debt, financial-obligation
Related Tickers: URGN
TL;DR
UroGen Pharma just took on a new financial obligation, filing an 8-K on 9/23.
AI Summary
UroGen Pharma Ltd. reported on September 23, 2024, that it has entered into a direct financial obligation. The filing does not specify the exact nature or amount of this obligation, but it is a material event requiring an 8-K filing.
Why It Matters
This filing indicates a new financial commitment or debt for UroGen Pharma Ltd., which could impact its financial health and future investment potential.
Risk Assessment
Risk Level: medium — The creation of a direct financial obligation can introduce new financial risks or opportunities that are not yet fully detailed, requiring further investigation.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
FAQ
What is the specific nature of the direct financial obligation UroGen Pharma Ltd. entered into?
The filing states that the registrant has entered into a direct financial obligation, but the specific details of this obligation are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 23, 2024.
What is UroGen Pharma Ltd.'s principal executive office address?
UroGen Pharma Ltd.'s principal executive offices are located at 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
What is the telephone number for UroGen Pharma Ltd.'s principal executive offices?
The telephone number is +1 (646) 768-9780.
What is the SIC code for UroGen Pharma Ltd.?
The Standard Industrial Classification (SIC) code for UroGen Pharma Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 895 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2024-09-24 16:15:51
Key Financial Figures
- $25,000,000 — (the "Tranche C Loan") in the amount of $25,000,000 was advanced on September 23, 2024 (the
Filing Documents
- d849854d8k.htm (8-K) — 26KB
- 0001193125-24-224801.txt ( ) — 145KB
- urgn-20240923.xsd (EX-101.SCH) — 3KB
- urgn-20240923_lab.xml (EX-101.LAB) — 18KB
- urgn-20240923_pre.xml (EX-101.PRE) — 11KB
- d849854d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 24, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer